Clinical Trial Update: Targeting Peroxisome Proliferator-activated Receptor-gamma in Peritoneal Dialysis Patients - Will it Reduce Inflammation, Atherosclerosis, Calcification and Improve Survival of Peritoneal Dialysis Patients? [NA]

View source ↗

Summary

A clinical trial update exploring targeting PPAR-gamma in peritoneal dialysis patients to reduce inflammation, atherosclerosis, and calcification and potentiall…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atherosclerosis
• Cardiovascular Disease
• Chronic Kidney Disease

Snippet

Sponsor: Hospital Authority, Hong Kong | Conditions: Chronic Disease, Kidney Diseases | NA | Status: UNKNOWN